Browse by Medical Category
Accepting New Patients
Dr. David Louis is Benjamin Castleman Professor of Pathology and chair of Mass General Pathology. His clinical practice and research focuses on the molecular basis of brain tumors and the application of molecular diagnostics to their classification.
Go To Programs
Go To Specialties
David N. Louis, MD, is the Benjamin Castleman Professor of Pathology at Harvard and chair of Pathology at Mass General Hospital. Dr. Louis' clinical practice and research has focused on the molecular basis of brain tumors and the application of molecular diagnostics to brain tumor classification. He has published more than 250 original articles, as well as numerous reviews, chapters and books. His laboratory was the first to demonstrate that molecular approaches could be used to subdivide malignant gliomas in a biologically relevant manner, and that molecular approaches could be used to predict the response of particular malignant gliomas to specific therapies, work that has led to worldwide adoption of molecular testing for the management of brain tumor patients. As a result, Dr. Louis co-chaired and was the primary editor for the 2007 WHO brain tumor classification and is currently guiding the WHO brain tumor revision expected in 2016. He has received prestigious awards for this work, has served on multiple advisory and editorial boards, and has authored and/or edited many of the major textbooks in neuropathology. He was co-chair of the Brain Tumor Progress Review Group sponsored by the NIH, and was the founding chair of the Cancer Biomarkers Study Section at the NIH. Under Dr. Louis? chairmanship, Mass General Pathology has become a national leader in molecular diagnostics and pathology informatics, leading to the development of the novel discipline of computational pathology.
Malignant gliomas of the cerebral hemispheres in adults are the most common brain tumors. They are the focus of the David N. Louis Laboratory efforts. Malignant gliomas are classified as astrocytomas, oligodendrogliomas, and oligoastrocytomas. The most aggressive, astrocytoma, is referred to as glioblastoma. Elucidating the molecular basis of glioma formation may impact both diagnostic and therapeutic aspects of clinical neuro-oncology.
Visit the David N. Louis Research Laboratory to learn more.
View my most recent publications at PubMed
2005 - Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma - JNEN (PDF)Supplementary Information Table 1.xls Supplementary Information Table 2.xls Supplementary Information Table 3.xls
View article on PubMed
Many ‘keen minds' have worked toward a better understanding of disease to enable improved diagnosis and treatment.
Back to Top